

FREZENT Biological Solutions

237 W 71 ST, 4FL
New York, NY, 10023



Natasha Shtraizent

T 917-930-3272

www.frezent.com

natasha@frezent.com

Industry

Biotech (Therapeutics)

Management

- Natasha Shtraizent, PhD
Founder, CEO - *Cancer biology*
- Lina Freage, PhD
Co-Founder, CSO –*Analytical Chemistry; Bio-conjugation*

Seeking to fill the roles:

- Chief Medical Officer
- Chief Biz. Dev. Officer

Advisory Board

- Dov Tamarkin, PhD
Founder and former CEO of therapeutics company Foamix
- Marshall Posner, MD
Director Head and Neck Medical Oncology, Icahn School of Medicine at Mount Sinai
- Dan Zekzer, MD PhD
Principal & Co-Founder of Match Discovery and Senior Analyst to Global Source Ventures, formerly Senior Director at Novo Nordisk and Director, Research Planning at Daiichi Sankyo
- Shani Peri, PhD
Technology & IP Development, Mayo Clinic Ventures; formerly, Teva Pharmaceuticals
- Eliyahu Efrat, PhD
Icahn School of Medicine at Mount Sinai, Animal Models
- Avital Weiss, PhD, MBA
Senior Program Manager, Taysha GTx

Number of employees : 2

Finance

- Auditor: BBCetc
- Financing to date: \$260K SBIR
- Financing sought: \$2M
For IND enabling studies

Legal

- Jenik Radon (Corporate)
- Wilson Sonsini (IP)

Business Description / Company Background:

FREZENT Biological Solutions is a therapeutic startup company developing a novel approach for targeting chemotherapy resistant dormant cancer cells to prevent recurrent head and neck cancer (HNC). The company was established based on the academic research conducted at Icahn School of Medicine at Mount Sinai by the founder, Dr. Natasha Shtraizent.

Market Opportunity / Unmet Need:

Global market for HNC therapeutics is estimated to reach 2.99B by 2030 (Precedence Research). In 2021, 68,000 people in the US and 660,000 people globally were diagnosed with HNC, the 6th leading cause of cancer-related mortality in the world. FREZENT has a bottom-up strategy, initially focusing on the rare types of HNC, including hypopharyngeal, laryngeal, and oral squamous cell carcinoma. Due to late diagnosis, these cancer types of HNC have extremely poor 5-year survival rates (20-30%). Moreover, the average disease control with standard of care for recurrent or metastatic disease is only 5-10 months. The estimated survival rate of this type of cancer is below average in comparison to other cancers i.e. stage I (53%), stage II (39%), stage III (36%) and stage IV (24%), which trend far below 50%. Over 60% of cases are diagnosed at stages III and IV. This low survival rate and clinical KOLs' opinions highlight the need for novel and more effective therapies specifically developed for HNC (National Cancer Institute, SEER Cancer Stat Facts).

Products / Services – Launched & Pipeline:

Our product is a biological small molecule inhibitor targeting an established mechanism for killing dormant cancer cells that escaped the effects of chemotherapy, in order to prevent their re-activation and recurrent disease.

Intellectual Property: FREZENT owns IP on the composition of matter and has joint IP with Mount Sinai for method of use (provisional application in preparation).

Commercial / Technical Milestones:

Achieved: In vitro POC demonstrated; IP generated; Scientific Advisory Board composed; non-diluted funds raised

Pending: Seed funding (2022); in vivo studies completed (2022); IND-enabling studies and IND application approval (2024); Series A funding (2024); Clinical trials Phase I and 2a and FDA approval for early access in rare type of cancer (2026); exit (2026)

Competition / Competitive Advantages / Customer Benefits:

We are well positioned within the competitive landscape. Competing technologies include novel combination therapies, currently in clinical trials, and emerging targeted inhibitors. Our competitive advantage is a new mechanism of action, potential for low toxicity, and high tolerability compared to chemical small molecule inhibitors. Additionally, we are developing an adjuvant therapy which will complement existing or novel therapies.

Financial Projections (Unaudited):

N/A since as a drug discovery company no revenues are expected in the first 5 years.